COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system

OBJECTIVE: Although recent evidence suggests no increased risk of severe COVID-19 outcomes associated with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) use, the relationship is less clear among patients with hypertension and diverse racial/ethnic groups. T...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Jaejin, Zhou, Hui, Wei, Rong, Luong, Tiffany Q., Gould, Michael K., Mefford, Matthew T., Harrison, Teresa N., Creekmur, Beth, Lee, Ming-Sum, Sim, John J., Brettler, Jeffrey W., Martin, John P., Ong-Su, Angeline L., Reynolds, Kristi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204813/
https://www.ncbi.nlm.nih.gov/pubmed/34155486
http://dx.doi.org/10.1016/j.ijchy.2021.100088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204813/
https://www.ncbi.nlm.nih.gov/pubmed/34155486
http://dx.doi.org/10.1016/j.ijchy.2021.100088

Ejemplares similares